Inactive Instrument

Neuralstem, Inc. Stock Nasdaq

US64127R3021

End-of-day quote Nasdaq
- ^USD	-

09-16	Palisade Bio, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM
08-11	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Last Transcript: Neuralstem, Inc.

Palisade Bio, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM

09-16

More transcripts

Analysts' recommendations: Neuralstem, Inc.

07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
01-09	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
17/11/23	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT

More recommendations

Press Releases: Neuralstem, Inc.

09-28	Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026	AQ
09-23	Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance	AQ
09-22	Palisade Bio Receives FDA Clearance of IND for PALI-2108 in Crohn’s Disease, Expanding Phase 2 Development Across IBD	AQ
09-21	Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum	AQ
09-03	Palisade Bio to Participate in Upcoming Investor Conferences	AQ

More press releases

News in other languages: Neuralstem, Inc.

30/01/24	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
29/01/24	LATE BRIEFING - Unternehmen und Märkte
29/01/24	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
29/01/24	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
29/01/24	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	251M 223M 208M 190M 358M 24.12B 361M 2.52B 976M 12.33B 942M 922M 39.58B	P/E 2026 *	-6.4x	P/E 2027 *	-5.21x
Enterprise Value	153M 136M 127M 116M 218M 14.73B 220M 1.54B 596M 7.53B 575M 563M 24.17B	EV / Sales 2026 *	429x	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

09-16	Palisade Bio, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 10:00 AM
08-11	Palisade Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
07-23	Oppenheimer Initiates Coverage on Palisade Bio With Outperform Rating, $8 Price Target	MT
06-30	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2500 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Index	CI
06-29	Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Value Benchmark	CI
06-29	Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial	DJ
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Value Benchmark Index	CI
06-29	Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study	MT
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Growth Benchmark Index	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Growth Benchmark	CI

	2026 *	2027 *
Net sales	357K 317K 296K 270K 509K 34.33M 514K 3.58M 1.39M 17.55M 1.34M 1.31M 56.33M	-
Net income	-47.86M -42.53M -39.69M -36.18M -68.23M -4.6B -68.86M -480M -186M -2.35B -180M -176M -7.55B	-63.05M -56.02M -52.28M -47.65M -89.88M -6.06B -90.71M -633M -245M -3.1B -237M -232M -9.94B
Net Debt	-97.7M -86.81M -81.02M -73.85M -139M -9.39B -141M -980M -380M -4.8B -367M -359M -15.41B	-335M -297M -278M -253M -477M -32.18B -482M -3.36B -1.3B -16.45B -1.26B -1.23B -52.79B

Neuralstem, Inc. Stock Nasdaq

Stocks

US64127R3021

Valuation: Neuralstem, Inc.

Latest news: Neuralstem, Inc.

Last Transcript: Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Financials

Company Profile